ZORMLIZ Trademark

Trademark Overview

On Thursday, November 19, 2015, a trademark application was filed for ZORMLIZ with the United States Patent and Trademark Office. The USPTO has given the ZORMLIZ trademark a serial number of 86825507. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 30, 2019. This trademark is owned by Glaxo Group Limited. The ZORMLIZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Vaccines
zormliz

General Information

Serial Number86825507
Word MarkZORMLIZ
Filing DateThursday, November 19, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 30, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 4, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 24, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Trademark Events

Event DateEvent Description
Monday, December 30, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 30, 2019ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 15, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 14, 2019EXTENSION 5 GRANTED
Thursday, May 9, 2019EXTENSION 5 FILED
Tuesday, May 14, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 9, 2019TEAS EXTENSION RECEIVED
Thursday, November 8, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 6, 2018EXTENSION 4 GRANTED
Tuesday, November 6, 2018EXTENSION 4 FILED
Tuesday, November 6, 2018TEAS EXTENSION RECEIVED
Saturday, May 26, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 24, 2018EXTENSION 3 GRANTED
Thursday, May 24, 2018EXTENSION 3 FILED
Thursday, May 24, 2018TEAS EXTENSION RECEIVED
Tuesday, October 10, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 6, 2017EXTENSION 2 GRANTED
Friday, October 6, 2017EXTENSION 2 FILED
Friday, October 6, 2017TEAS EXTENSION RECEIVED
Saturday, May 27, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 25, 2017EXTENSION 1 GRANTED
Thursday, May 25, 2017EXTENSION 1 FILED
Thursday, May 25, 2017TEAS EXTENSION RECEIVED
Tuesday, November 29, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 4, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 4, 2016PUBLISHED FOR OPPOSITION
Wednesday, September 14, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, August 27, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Saturday, August 20, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 16, 2016EXAMINER'S AMENDMENT ENTERED
Tuesday, August 16, 2016ASSIGNED TO LIE
Tuesday, August 16, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, August 16, 2016EXAMINERS AMENDMENT E-MAILED
Tuesday, August 16, 2016EXAMINERS AMENDMENT -WRITTEN
Monday, March 14, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 14, 2016NON-FINAL ACTION E-MAILED
Monday, March 14, 2016NON-FINAL ACTION WRITTEN
Friday, March 11, 2016ASSIGNED TO EXAMINER
Tuesday, November 24, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 23, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

zormliz system pharmaceutical disorders preparations treatment tissue substances genitourinary respiratory skeletal